Compare Gilead Sciences, Inc. (GILD) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Banco Santander SA — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $168.35B), while Banco Santander SA trades at $14.85 (market cap $211.63B). The key difference: Banco Santander SA is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | SAN | |
|---|---|---|
Market Cap | $168.35B | $211.63B |
Sector | Health | Financials |
52-Week High | $155.80 | $14.71 |
52-Week Low | $110.56 | $9.37 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Banco Santander (SAN) trades at $14.83, up 0.92% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 earnings, beating estimates in Q1 but missing in Q2, while net income grew to $14.10 billion in 2025. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, enhancing its U.S. footprint.
Outlook is supported by analyst consensus (64% buy ratings) and record profitability, but risks include volatile earnings, high debt levels, and integration challenges from acquisitions. The stock's valuation appears reasonable with a P/E of 14.4, offering potential for growth if execution remains strong amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
